Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

A. Larson, Richard; L. Sievers, Eric; A. Stadtmauer, Edward; Löwenberg, Bob; H. Estey, Elihu; Dombret, Hervé; Theobald, Matthias; Voliotis, D.; M. Bennett, John; Richie, Maria; Leopold, Lance; S. Berger, Mark; L. Sherman, Matthew; R. Loken, Michael; J. M. van Dongen, Jacques; D. Bernstein, Irwin; R. Appelbaum, Frederick; Study Group, Mylotarg

doi:10.1002/cncr.21326

Public

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

Published in Cancer • Aug 22, 2005

Authors:

Richard A. Larson

Eric L. Sievers

Edward A. Stadtmauer

Abstract

BACKGROUND: In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS: Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, P...

Subject

Medicine

Gemtuzumab ozogamicin

Gastroenterology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!